LONDON, UK / ACCESSWIRE / September 26, 2016 / Active Wall St. blog coverage looks at the headline from Endo International PLC (NASDAQ: ENDP) ("Endo") as the company announced on September 23, 2016, that its Board of Directors had chosen Paul V. Campanelli as the new President and Chief Executive Officer, and he will take charge immediately. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

Today, AWS is promoting its blog coverage on ENDP. Get all of our free blog coverage and more by clicking on the link below: http://www.activewallst.com/registration-3/?symbol=ENDP.

Brands such as Zydone, Lidoderm and Percocet, as well as a number of generic drugs.

About the new CEO

Paul Campanelli will be taking over the reins from Rajiv De Silva, who has resigned from his position as President and CEO and as member of the Board. Paul will also take over the position as a member of the Board. Paul is currently heading Endo's generic and OTC drugs' business, Par Pharmaceutical. Paul had joined Endo in 2015 when Endo had acquired Par for $8 billion, where he was the CEO since 2012. The generic and OTC drugs account for around 60% of Endo's total revenues for 2H16.

Commenting on Paul's appointment, Roger H. Kimmel, Chairman of the Board of Endo said:

"Paul has spent a significant portion of his career leading and operating complex generics businesses and overseeing Par's branded business. The Board believes his experience positions him to drive a broad range of growth initiatives across Endo's entire portfolio, generating better health outcomes for patients and creating value for Endo's shareholders."

Industry experts feel that Paul's appointment indicates Endo's strategic shift in focus towards the generic drugs business. Endo's stock has been under tremendous pressure as a result of piling debts due to various acquisitions. In June 2016, Endo had held discussion with several private equity firms for the sale of its assets to reduce its huge debt of $8 billion.

About the predecessor

Rajiv had joined Endo in March 2013 from Valeant Pharmaceuticals where he was President. Rajiv had strategically used the acquisitions route to drive Endo's growth and revenues. In fact, Rajiv had helmed the acquisition of Par, where Paul heading their generic and OTC business.

At Valeant he was responsible for the multi-fold increase in revenues through acquisitions and organic sales growth. His efforts put Valeant in a leadership position in the industry. Before joining Valeant, Rajiv was with Novartis from 2003 to 2008 and held various senior level positions. Earlier in his career, he was a Principal at McKinsey & Company's global Pharmaceutical and Medical Products practice. He holds a Bachelor of Science in Civil Engineering from Princeton University, a Master's of Science in Civil Engineering from Stanford University, and a Masters of Business Administration from the University of Pennsylvania's Wharton School.

Commenting on Rajiv's tenure, Roger H. Kimmel said:

"He played a critical role in assembling valuable assets, establishing a global footprint and in building strong teams."

Stock Performance

Endo's shares which had been steadily on a decline since early 2016 received a boost on the news of change in leadership in the company. The stock closed the trading session at $23.39, surging 15.45% from its previous closing price of $20.26, on last Friday. A total volume of 21.09 million shares have exchanged hands, which was higher than the 3-month average volume of 6.99 million shares. Endo International's stock price advanced 5.89% in the last month and rallied 57.51% in the past three months.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street